Global Huntington's Disease Therapeutics Market 2017-2021

This industry research report identifies F. Hoffmann-La Roche, H. Lundbeck, Prana Biotechnology, and Teva Pharmaceutical Industries as the key vendors in the global Huntington’s disease therapeutics market. This industry research report also presents a competitive analysis of the market by drug class (Antidopaminergics, Anticonvulsants, Antipsychotics, and Antidepressants) and by geography (the Americas, APAC, and EMEA).

Overview of the global Huntington’s disease therapeutics market

Technavio’s market research analysis identifies the early onset of disease symptoms that increases the demand for Huntington’s disease (HD) therapeutics as one of the primary growth factors for the Huntington’s disease therapeutics market. HD is equally prevalent in both males and females and affects people irrespective of their ethnicity. The disease symptoms may appear anytime in the individual’s life and the etiology is genetic. The person who inherits the mutated genes from their affected parents will probably suffer from the disease sometime in their lifetime. According to our market research analysts, this market will grow steadily at a CAGR of around 15% by 2021.

The advancements in science and the introduction of nanotechnologies has resulted in modern techniques such as bioinformatics, molecular targeting, nanotechnology, and personalized medicines that has facilitated drug development to cure neurodegenerative disorders. The advancements have resulted in the better understanding of the pathogenesis of disease at genetic and molecular level that further results in the discovery of new targets for therapy and disease modifying drugs. Intensive R&D has resulted in the identification of an enzyme that can potentially reverse the progression of HD. This research analysis identifies the advancements in biomedical sciences as one of the key trends behind the growth of the Huntington’s disease therapeutics market.

Competitive landscape and key vendors

The Huntington’s disease therapeutics market is fragmented due to the presence of several large and small vendors who are focusing on consolidating their market shares through strategic alliances and acquisitions. Government support in terms of granting orphan drug designation, major patent expiries, and the rising awareness about HD, are major factors that play a significant role in the performance of the vendors in this marketspace.

The leading vendors in the market are -

• F. Hoffmann-La Roche
• H. Lundbeck
• Prana Biotechnology
• Teva Pharmaceutical Industries

The other prominent vendors in the market are Intellect Neurosciences, Horizon Pharma, Sangamo Therapeutics, and Vertex Pharmaceuticals.

Segmentation by drug class and analysis of the Huntington’s disease therapeutics market

• Antidopaminergics
• Anticonvulsants
• Antipsychotics
• Antidepressants

Owing to their effect on reversible depletion of monoamines including dopamine, Antidopaminergics agents are primarily suitable to treat chorea, which is the most common problem associated with HD. Tetrabenazine (TBZ) is primarily used for pharmacological and the symptomatic treatment of chorea associated with HD due to their therapeutic efficacy.

Geographical segmentation and analysis of Huntington’s disease therapeutics market

• Americas
• APAC
• EMEA

The Americas is witnessing increasing incidences of HD. The availability of increased patient pool and the rise in government initiatives boost the research and development of novel therapeutics for the treatment of HD. The rising investments towards the launch of new drugs for the treatment of chorea will positively influence the growth of the Huntington’s disease therapeutics market in this region.

Key questions answered in the report include

• What will the huntington’s disease therapeutics market size and growth rate be in 2021?
• What are the key factors driving the global Huntington’s disease therapeutics market?
• What are the key market trends impacting the growth of the global Huntington’s disease therapeutics market?
• What are the challenges to market growth?
• Who are the key vendors in the global Huntington’s disease therapeutics market?
• What are the market opportunities and threats faced by the vendors in the global Huntington’s disease therapeutics market?
• Trending factors influencing the market shares of the Americas, APAC, and EMEA.
• What are the key outcomes of the five forces analysis of the global Huntington’s disease therapeutics market?

Technavio also offers customization on reports based on specific client requirement